NVE Corporation (NVEC) is rated a long-term Buy due to its proprietary spintronics technology, expanding medical-device market presence, and robust profitability. NVEC's ultraminiature magnetic sensors target implantable medical devices, leveraging strong relationships with manufacturers like Abbott Laboratories and recent manufacturing expansions. FY2026 net profit margin reached 58%, with Q1 FY2027 revenue and net income up 81% and 79% respectively, demonstrating accelerating growth momentum.
NVEC's Q1 results reflect strong revenue growth, higher earnings, and momentum from new products, robotics and AIoT opportunities.
NVE Corporation (NVEC) Q1 2027 Earnings Call Transcript
| Semiconductors & Semiconductor Equipment Industry | Information Technology Sector | Peter G. Eames CEO | XMUN Exchange | US6294452064 ISIN |
| US Country | 41 Employees | 3 Aug 2026 Last Dividend | 22 Nov 2002 Last Split | 26 Sep 1996 IPO Date |
NVE Corporation is at the forefront of nanotechnology through its development and sale of devices that utilize spintronics—a sophisticated technology that leverages the spin of electrons to process, store, and communicate information. With a global presence in the United States and beyond, the company is dedicated to the innovation and manufacturing of spintronic products. Their offerings include an array of sensors and couplers designed for data acquisition and transmission. Founded in 1989, NVE Corporation has established its headquarters in Eden Prairie, Minnesota. The firm is also engaged in research and development contracts and licenses its technology for spintronic magnetoresistive random access memory (MRAM).